{"ticker": {"uuid": "1580ebd3-ae75-4975-8a7a-9ddfbbd9f7e5", "symbol": "PTX", "name": "Prescient Therapeutics Limited", "exchange": "ASX", "country": "AU", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Prescient Therapeutics (ASX:PTX) Jumps: Could Its Cancer-Therapy Pipeline Become the Next ASX Biotech Catalyst?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOY1lPTVJtamRaLWZMdjczQ2M4emZzUDFHdzlOdVFHZ1RtbHl2Q1MzWWRweFNYX1lxTC0xX1FxSUVCc2NCLTdTbmx3MkNKczd0NDU4RzNVSldESFlDZzRqZXVoNGxFWDh5SHVSQ0d6bWN3NlMyd3JuVnN1SjZJc1g3alYwemxkZW9yM3RvcThIRmFUdGZkaVppdVRfdmNCazJ2UnZBTTZGUlJXVkh6S2pBSEtpRXJVcW9zZGpTMHJnbjNtdDMxSlhySnNpX3lncU1HVi1Kbmw0WmFGcW1jaXc?oc=5", "source_name": "Kalkine", "published_at": "2026-07-13T07:14:00+00:00", "published_display": "13 Jul 2026 07:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Prescient Therapeutics (ASX:PTX) Tops Biotech Penny Watchlists", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNMnAtQlZLWmp2Nm9NRzcySk1ZbnkxdlljRXRlZlotV0phUlJlUzJJb3I0ZW9SeEJENjF2RzlzRTlaVnVZTlhzWksyR1EyeGdIeXcxempDNHZXajJQQmJ2ZjdjNU1lWGJwSnNfWE81MFVwNXZVeXZVLV9acFNucUZyQlJ2UElMc0lXV0kyVjFIYnBMRzJsS0xCbFVnaUhaQkRHYWJJSGlsSQ?oc=5", "source_name": "Kalkine Media", "published_at": "2026-07-12T15:15:00+00:00", "published_display": "12 Jul 2026 15:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Prescient Therapeutics (ASX:PTX) Remains on ASX Biotech Watchlists", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNczIwVW52UUxDTlMyOVJfR296SEpxbHlFTHE0MzJXUHE1U3FnaTZjYUZJY05yQjZfbUh2NkVWZUNYMS1sMXQwd0I2b2hVUFNmOGZXSzRBYXM5aUQydm8xZm1vME52Nzg0dGk2Q3NBTXVFZnRqblNKZHh0UzB0aFBwTmYyXzhMRDllbVlBcUh5U0NDeWdjQlVNcU5kVEZLbjN6clJxamxQeDRiU0Mx?oc=5", "source_name": "Kalkine Media", "published_at": "2026-07-10T04:43:00+00:00", "published_display": "10 Jul 2026 04:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prescient Therapeutics Cleans Up Capital Structure as 4 Million Options Expire", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQX3dWWXNKNVlVNWZDclNySnpTcV9FWWk0TUR2VVA0LW1rbVVhQldkU2l5LWpCN2NTMHNaSVAyZUo3WkxubTFrdC1OczMydkx1VTNlVkgzOXdUbGRScjIzT004Yzc2X2Q1Njc0UVI2TG9YSjhXLWNySmRwS1ZYUWF5SDJBMkhEWjREMDNtY25pR2lKeURPbXhNSFNLSFNQaGxlZmh2ZFZZUnd3dm43NUxObHpxc3ZKakVLYlJPZjV0clh4SlU1czR5YkpB?oc=5", "source_name": "TipRanks", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Prescient (ASX:PTX) Share Price Fall 9% Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNUURKUklBajVqQnN3djdPVVpwWmJSN1Y3am1CVlhxMWZXYjFtZS1RQVlkWXp0bllyS1hzTkoyV0o5dXZqbWZBQ29oOHlhQkZYNW9ITGdjY2Npc3BJUWJhWEVsUm1MS0c4YktOYVJ0b0tyNE5hRzRwSFR3UnN4QVExVVhuQlJvRDA1R0RiUjdwX0tpMWkw?oc=5", "source_name": "Kalkine", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prescient Therapeutics ramps up Phase 2 trial as research reiterates valuation upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxNSk1yeXFlNGlxbWhQWmZKSmV0czl1dkphVlh5VDVPdFBhdWlnVzNSOTFwb2M2SW1aRk5BSko5UWczb01fT2tQcGpST2lyVFR1ZG00QkV4ZlVMT2tNTXFQblZJQTIzZHZDSTBGdmRfWERsZVctZWlMalFGUzBkNGcyaUVkSEdfYWlxMllSS3R5dlZvUk0xQkMxMVNaYmVuSmxJZWJTc2RPLWx4Q2t6RlFNc1htMHdmZFJJUFhNUEJtaGFTVVViSFctNWRLNFRzZG5tRE0wZHVwWWxRbDV2dnUyeXhwTlppTmFORXp6VGxLRlc?oc=5", "source_name": "Proactive financial news", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insights: Prescient Therapeutics Ltd (ASX:PTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE9TZjk0X0J0MzlpMmZyVG9OZk9uU3hmNVhCZ2FMOThCXzFuYnlLdG1jaXJ2MDJGOUo4R3A0Ri05cGdYaW10aUppak55TzRMMTZF?oc=5", "source_name": "smallcaps.com.au", "published_at": "2025-10-30T14:16:07+00:00", "published_display": "30 Oct 2025 14:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "One Healthcare Stock Taking Strategic Initiatives to Target Growing Oncology Market - Prescient Therapeutics Limited", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTFBZRTdJTEs3WFFDSWVIOHdwcXJjT3lmV0lGVWg3LVIzT0xCY3ZKV2xwUlJKN1NxaG5JbG83eGJtR2xTVFJiRjMtc3RsNXVmcmFUQjZ3RmR3OVhqX08zLWVMd2NXZ1N6SXJ6dHp3TnNn?oc=5", "source_name": "Kalkine", "published_at": "2025-08-23T22:43:36+00:00", "published_display": "23 Aug 2025 22:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "As Prescient Therapeutics kicks off Phase 2 trial for PTX-100, analysts raise valuation", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxNclFfUVJnUjRsNTFVNXJpQm5aSVl6UHNDUGdZNjBCR0RvZFk4R0YxYVRnNm9kSkg3MTByNjdkeDFnS0VHaThZWkhDSkZKRlIxa1FDd1VLYUo0aExFZU02WHR3MHdubUFVeHdBM0RxcGtVWnFRZDE4QWtEN1VMcXNhczRCbGk2YkNaVmxOcXhoSURiZ2J1YVl1WkRfZEMwMkMwUnNBSkFDNUpIdGIxTk4xdDJUaHFRZjFoaDhwMjk1YXAxaGdVZ202N3BhbVhXaUdIX1RnQ2xvWG5oZTJKanVGcGpMOGp3R1RrMVpiY1VvSTNkdw?oc=5", "source_name": "Proactive financial news", "published_at": "2025-07-08T07:00:00+00:00", "published_display": "08 Jul 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer cure no longer science fiction: Prescient boss", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Australian", "published_at": "2023-04-02T07:00:00+00:00", "published_display": "02 Apr 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Prescient Therapeutics (ASX:PTX) Jumps: Could Its Cancer-Therapy Pipeline Become the Next ASX Biotech Catalyst?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOY1lPTVJtamRaLWZMdjczQ2M4emZzUDFHdzlOdVFHZ1RtbHl2Q1MzWWRweFNYX1lxTC0xX1FxSUVCc2NCLTdTbmx3MkNKczd0NDU4RzNVSldESFlDZzRqZXVoNGxFWDh5SHVSQ0d6bWN3NlMyd3JuVnN1SjZJc1g3alYwemxkZW9yM3RvcThIRmFUdGZkaVppdVRfdmNCazJ2UnZBTTZGUlJXVkh6S2pBSEtpRXJVcW9zZGpTMHJnbjNtdDMxSlhySnNpX3lncU1HVi1Kbmw0WmFGcW1jaXc?oc=5", "source_name": "Kalkine", "published_at": "2026-07-13T07:14:00+00:00", "published_display": "13 Jul 2026 07:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Prescient Therapeutics (ASX:PTX) Tops Biotech Penny Watchlists", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNMnAtQlZLWmp2Nm9NRzcySk1ZbnkxdlljRXRlZlotV0phUlJlUzJJb3I0ZW9SeEJENjF2RzlzRTlaVnVZTlhzWksyR1EyeGdIeXcxempDNHZXajJQQmJ2ZjdjNU1lWGJwSnNfWE81MFVwNXZVeXZVLV9acFNucUZyQlJ2UElMc0lXV0kyVjFIYnBMRzJsS0xCbFVnaUhaQkRHYWJJSGlsSQ?oc=5", "source_name": "Kalkine Media", "published_at": "2026-07-12T15:15:00+00:00", "published_display": "12 Jul 2026 15:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Prescient Therapeutics (ASX:PTX) Remains on ASX Biotech Watchlists", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNczIwVW52UUxDTlMyOVJfR296SEpxbHlFTHE0MzJXUHE1U3FnaTZjYUZJY05yQjZfbUh2NkVWZUNYMS1sMXQwd0I2b2hVUFNmOGZXSzRBYXM5aUQydm8xZm1vME52Nzg0dGk2Q3NBTXVFZnRqblNKZHh0UzB0aFBwTmYyXzhMRDllbVlBcUh5U0NDeWdjQlVNcU5kVEZLbjN6clJxamxQeDRiU0Mx?oc=5", "source_name": "Kalkine Media", "published_at": "2026-07-10T04:43:00+00:00", "published_display": "10 Jul 2026 04:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prescient Therapeutics Cleans Up Capital Structure as 4 Million Options Expire", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQX3dWWXNKNVlVNWZDclNySnpTcV9FWWk0TUR2VVA0LW1rbVVhQldkU2l5LWpCN2NTMHNaSVAyZUo3WkxubTFrdC1OczMydkx1VTNlVkgzOXdUbGRScjIzT004Yzc2X2Q1Njc0UVI2TG9YSjhXLWNySmRwS1ZYUWF5SDJBMkhEWjREMDNtY25pR2lKeURPbXhNSFNLSFNQaGxlZmh2ZFZZUnd3dm43NUxObHpxc3ZKakVLYlJPZjV0clh4SlU1czR5YkpB?oc=5", "source_name": "TipRanks", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Prescient (ASX:PTX) Share Price Fall 9% Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNUURKUklBajVqQnN3djdPVVpwWmJSN1Y3am1CVlhxMWZXYjFtZS1RQVlkWXp0bllyS1hzTkoyV0o5dXZqbWZBQ29oOHlhQkZYNW9ITGdjY2Npc3BJUWJhWEVsUm1MS0c4YktOYVJ0b0tyNE5hRzRwSFR3UnN4QVExVVhuQlJvRDA1R0RiUjdwX0tpMWkw?oc=5", "source_name": "Kalkine", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prescient Therapeutics ramps up Phase 2 trial as research reiterates valuation upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxNSk1yeXFlNGlxbWhQWmZKSmV0czl1dkphVlh5VDVPdFBhdWlnVzNSOTFwb2M2SW1aRk5BSko5UWczb01fT2tQcGpST2lyVFR1ZG00QkV4ZlVMT2tNTXFQblZJQTIzZHZDSTBGdmRfWERsZVctZWlMalFGUzBkNGcyaUVkSEdfYWlxMllSS3R5dlZvUk0xQkMxMVNaYmVuSmxJZWJTc2RPLWx4Q2t6RlFNc1htMHdmZFJJUFhNUEJtaGFTVVViSFctNWRLNFRzZG5tRE0wZHVwWWxRbDV2dnUyeXhwTlppTmFORXp6VGxLRlc?oc=5", "source_name": "Proactive financial news", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insights: Prescient Therapeutics Ltd (ASX:PTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE9TZjk0X0J0MzlpMmZyVG9OZk9uU3hmNVhCZ2FMOThCXzFuYnlLdG1jaXJ2MDJGOUo4R3A0Ri05cGdYaW10aUppak55TzRMMTZF?oc=5", "source_name": "smallcaps.com.au", "published_at": "2025-10-30T14:16:07+00:00", "published_display": "30 Oct 2025 14:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "One Healthcare Stock Taking Strategic Initiatives to Target Growing Oncology Market - Prescient Therapeutics Limited", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTFBZRTdJTEs3WFFDSWVIOHdwcXJjT3lmV0lGVWg3LVIzT0xCY3ZKV2xwUlJKN1NxaG5JbG83eGJtR2xTVFJiRjMtc3RsNXVmcmFUQjZ3RmR3OVhqX08zLWVMd2NXZ1N6SXJ6dHp3TnNn?oc=5", "source_name": "Kalkine", "published_at": "2025-08-23T22:43:36+00:00", "published_display": "23 Aug 2025 22:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "As Prescient Therapeutics kicks off Phase 2 trial for PTX-100, analysts raise valuation", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxNclFfUVJnUjRsNTFVNXJpQm5aSVl6UHNDUGdZNjBCR0RvZFk4R0YxYVRnNm9kSkg3MTByNjdkeDFnS0VHaThZWkhDSkZKRlIxa1FDd1VLYUo0aExFZU02WHR3MHdubUFVeHdBM0RxcGtVWnFRZDE4QWtEN1VMcXNhczRCbGk2YkNaVmxOcXhoSURiZ2J1YVl1WkRfZEMwMkMwUnNBSkFDNUpIdGIxTk4xdDJUaHFRZjFoaDhwMjk1YXAxaGdVZ202N3BhbVhXaUdIX1RnQ2xvWG5oZTJKanVGcGpMOGp3R1RrMVpiY1VvSTNkdw?oc=5", "source_name": "Proactive financial news", "published_at": "2025-07-08T07:00:00+00:00", "published_display": "08 Jul 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer cure no longer science fiction: Prescient boss", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Australian", "published_at": "2023-04-02T07:00:00+00:00", "published_display": "02 Apr 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 83, "total_relevant": 11, "sentiment_summary": {"positive": 2, "negative": 1, "neutral": 8, "score": 51, "total": 11, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 89, "events": [{"event": "general", "label": "Market update", "weight": 4.95, "count": 9}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 2, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 0.07, "latest_week": "2026-07-10", "one_week_move": 5.9, "four_week_move": 5.9, "twelve_week_move": 41.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.441711, "market_dynamics_buy_signal": false, "relative_strength": 19.261232, "fair_value_gap": 31.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 42.2383, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+5.9% over one week, +5.9% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Kalkine", "count": 3}, {"label": "Kalkine Media", "count": 2}, {"label": "Proactive financial news", "count": 2}, {"label": "TipRanks", "count": 1}, {"label": "simplywall.st", "count": 1}, {"label": "smallcaps.com.au", "count": 1}, {"label": "The Australian", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 11}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 9}, {"label": "Balance sheet", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "89/100 classification confidence."}, {"label": "Company focus", "value": "11", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+5.9% over one week, +5.9% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Prescient Therapeutics (ASX:PTX) Jumps: Could Its Cancer-Therapy Pipeline Become the Next ASX Biotech Catalyst?"}], "updated_at": "2026-07-18T02:27:35.019549+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}